News Results
There are 613,358 News Results
May 27, 2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
May 28, 2018
LONDON, May 29, 2018 /PRNewswire/ -- A billion-dollar industry has sprung up virtually overnight. Cannabis has gone from taboo to big business, and most of it is happening in Canada,...
May 28, 2018
EL AL Announced Today its Financial Results for the First Quarter of 2018
May 29, 2018
LONDON, May 30, 2018 /PRNewswire/ -- FN Media Group Presents OilPrice.com News Commentary In a matter of weeks, Canada will most likely legalize marijuana for recreational use. Expectations for a...
May 31, 2018
Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
May 31, 2018
Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone
May 31, 2018
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström's Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin's Lymphoma
Jun 1, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
Jun 2, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Jun 5, 2018
INDIANAPOLIS, June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for...
